【ChiCTR1900024372】Communication and management of incidental pathology in 1,214 consecutive appendicectomies: a cohort study
ChiCTR1900024372
结束
/
/
/
2019-07-07
/
/
Important incidental pathology on appendicectomy speciment.
Communication and management of incidental pathology in 1,214 consecutive appendicectomies: a cohort study
Communication and management of incidental pathology in 1,214 consecutive appendicectomies: a cohort study
3011
Important incidental pathology requiring further action is commonly found during appendicectomy, macro- and microscopically. This study aims to assess whether the introduction of an acute surgical unit impacted the disclosure and management of patients with important incidental findings during appendicectomy.
连续入组
回顾性研究
Nil; this is a retrospective cohort study.
Nil; this is a retrospective cohort study.
N Kinnear received funding in relation to this work from the University of Adelaide, the Hospital Research Foundation and the National Health and Medical Research Council.
/
1200
/
2010-02-01
2015-07-31
/
Patients undergoing appendicectomy at our institution between 01/02/2010 and 31/01/2015.；
请登录查看Patients with incomplete data.；
请登录查看Dr Ned Kinnear
3011
Dr Ned Kinnear的其他临床试验
澳大利亚维多利亚省西部卫生的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04